Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors

被引:5
作者
Horiuchi, Kentaro [1 ]
Kogiso, Tomomi [1 ]
Sagawa, Takaomi [1 ]
Taniai, Makiko [1 ]
Kotera, Yoshito [2 ]
Egawa, Hiroto [2 ]
Tokushige, Katsutoshi [1 ]
机构
[1] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, 8-1 Kawada Cho,Shinju Ku, Tokyo 1628666, Japan
[2] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, 8-1 Kawada Cho,Shinju Ku, Tokyo 1628666, Japan
关键词
Fatty liver disease (FLD); Liver transplantation (LT); Everolimus (EVL); SIMPLE NONINVASIVE INDEX; NONALCOHOLIC STEATOHEPATITIS; SIGNIFICANT FIBROSIS; STEATOSIS; CYCLOSPORINE; TACROLIMUS; DIAGNOSIS; CIRRHOSIS; PREDICT;
D O I
10.1016/j.aohep.2022.100670
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and objectives: Fatty liver disease (FLD) may develop in liver transplant recipients. We investigated the recipient and donor risk factors for FLD development after liver transplantation (LT).Methods: A total of 108 liver transplant recipients (54 men [50.0%]; median age, 52 [20-68] years) treated from 2011-2020 was enrolled. Three recipients died at < 3 months as a result of infection or blood flow impairment, and were excluded from the long-term FLD study. On evaluation of 88 prospective living donors, fatty liver was observed in 21. The prevalence and risk factors for FLD and survival were evaluated.Results: After LT, 28 of 105 recipients (26.7%) developed FLD. FLD was more common in patients with a high body mass index (BMI) and dyslipidemia (both p < 0.01), primary nonalcoholic steatohepatitis (p = 0.02), after living-donor LT (p = 0.03) and everolimus (EVL) use (p = 0.08). Factors predictive of FLD included EVL use and a high BMI (hazard ratios = 3.00 and 1.34; p = 0.05 and p < 0.01, respectively). Sixteen donors lost 6.5 kg (range: 2.0-16.0 kg) of body weight prior to LT. However, there were no cases of primary non -function, which did not affect the FLD prevalence. Development of FLD did not have a negative impact on LT outcome; the 5-year survival rate was 92.6%. Conclusions: Recipient factors were more important than donor factors for FLD onset after LT. (c) 2022 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 34 条
  • [11] Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection
    Haegele, Stefanie
    Reiter, Silvia
    Wanek, David
    Offensperger, Florian
    Pereyra, David
    Stremitzer, Stefan
    Fleischmann, Edith
    Brostjan, Christine
    Gruenberger, Thomas
    Starlinger, Patrick
    [J]. PLOS ONE, 2016, 11 (11):
  • [12] Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation
    Jun, Mi-Jung
    Shim, Ju Hyun
    Kim, So Yeon
    Seo, Nieun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Yu, Eunsil
    Lee, Sung-Gyu
    [J]. LIVER TRANSPLANTATION, 2014, 20 (04) : 437 - 445
  • [13] Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
    Kim, Hyung Duk
    Chang, Ji-Yeun
    Chung, Byung Ha
    Kim, Chan-Duck
    Lee, Sang-Ho
    Kim, Yeong Hoon
    Yang, Chul Woo
    [J]. ANNALS OF TRANSPLANTATION, 2021, 26 : 1 - 12
  • [14] Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
    Leite, Nathalie C.
    Salles, Gil F.
    Araujo, Antonio L. E.
    Villela-Nogueira, Cristiane A.
    Cardoso, Claudia R. L.
    [J]. LIVER INTERNATIONAL, 2009, 29 (01) : 113 - 119
  • [15] Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis
    Love, Sharma
    Mudasir, Malik A.
    Bhardwaj, Subhash C.
    Singh, Gurdarshan
    Tasduq, Sheikh A.
    [J]. ONCOTARGET, 2017, 8 (69) : 113403 - 113417
  • [16] Liver Transplantation in Patients With Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
    Malik, Shahid M.
    Gupte, Parijat A.
    de Vera, Michael E.
    Ahmad, Jawad
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (07) : 800 - 806
  • [17] Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-analysis
    McAlister, V. C.
    Haddad, E.
    Renouf, E.
    Malthaner, R. A.
    Kjaer, M. S.
    Gluud, L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (07) : 1578 - 1585
  • [18] Liver transplantation using fatty livers: Always feasible?
    McCormack, Lucas
    Dutkowski, Philipp
    El-Badry, Ashraf Mohammad
    Clavien, Pierre-Alain
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 (05) : 1055 - 1062
  • [19] Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests
    Minervini, Marta I.
    Ruppert, Kristine
    Fontes, Paulo
    Volpes, Riccardo
    Vizzini, Giovanni
    de Vera, Michael E.
    Gruttadauria, Salvatore
    Miraglia, Roberto
    Pipitone, Loredana
    Marsh, J. Wallis
    Marcos, Amadeo
    Gridelli, Bruno
    Demetris, Anthony J.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 50 (03) : 501 - 510
  • [20] Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation
    Narayanan, Praveena
    Mara, Kristin
    Izzy, Manhal
    Dierkhising, Ross
    Heimbach, Julie
    Allen, Alina M.
    Watt, Kymberly D.
    [J]. TRANSPLANTATION, 2019, 103 (01) : e14 - e21